Hematologic Oncology Update
- Episodes
- 176
- Released
- several times a week
- Latest episode
- Nov 14, 2026
About the podcast
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
Episodes 176
Follicular Lymphoma — Where We Are, Where We're Headed in the Use of Bispecific Antibodies
Featuring perspectives from Prof Chan Chea and Dr Matthew Matasar, including the following topics:Introduction (0:00)Prologue: Saturday Night Fever (1:35)Baby Boomers' Guide to Mechanisms of Action …
Show notes
Featuring perspectives from Prof Chan Chea and Dr Matthew Matasar, including the following topics:
- Introduction (0:00)
- Prologue: Saturday Night Fever (1:35)
- Baby Boomers' Guide to Mechanisms of Action (3:07)
- Second-Line Treatment (12:36)
- Complications Associated with Bispecific Antibodies (23:41)
- Case Presentations (25:52)
- New Bispecific T-Cell Engagers — Surovatamig (26:24)
- Other Novel Agents (50:05)
Chapters (8)
Relapsed/Refractory Multiple Myeloma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Featuring perspectives from Dr Sagar Lonial and Dr Paul G Richardson, including the following topics:Multiple Myeloma (0:00)Introduction: ESMO 2026; Recent FDA Approvals (1:53)Chimeric Antigen Receptor T-Cell …
Show notes
Featuring perspectives from Dr Sagar Lonial and Dr Paul G Richardson, including the following topics:
- Multiple Myeloma (0:00)
- Introduction: ESMO 2026; Recent FDA Approvals (1:53)
- Chimeric Antigen Receptor T-Cell Therapy — Dr Lonial (2:46)
- Bispecific Antibodies — Dr Lonial (19:16)
- Antibody-Drug Conjugates — Dr Richardson (37:08)
- Up-Front Treatment; Cereblon E3 Ligase Modulators — Dr Richardson (50:10)
Chapters (6)
Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens
Featuring an interview with Dr Matthew Lunning, including the following topics:Bispecific antibody/antibody-drug conjugate combinations (0:00)A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD …
Show notes
Featuring an interview with Dr Matthew Lunning, including the following topics:
- Bispecific antibody/antibody-drug conjugate combinations (0:00)
- A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07)
Chapters
Loading chapters …
Diffuse Large B-Cell Lymphoma — A Grand Rounds Program
Featuring a presentation by Dr Matthew Matasar, including the following topics:Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)Clinician Survey Results Regarding …
Show notes
Featuring a presentation by Dr Matthew Matasar, including the following topics:
- Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)
- Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41)
- Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01)
- Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47)
- Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34)
- Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31)
- Discussion of Questions from the Community (50:20)
Chapters
Loading chapters …
Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 1: An Interview with Dr Matthew Lunning on CNS Prophylaxis
Featuring an interview with Dr Matthew Lunning, including the following topics:A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00)CNS …
Show notes
Featuring an interview with Dr Matthew Lunning, including the following topics:
- A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00)
- CNS prophylaxis in non-Hodgkin lymphoma (7:58)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 6
Featuring perspectives from Dr Lindsey Roeker, including the following topics:Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives …
Show notes
Featuring perspectives from Dr Lindsey Roeker, including the following topics:
- Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)
- Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46)
- Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 5
Featuring perspectives from Dr Lindsey Roeker, including the following topics:Consensus Approach to optimizing front-line treatment (0:00)Emerging role of sonrotoclax (8:39)Bruton tyrosine kinase inhibitor …
Show notes
Featuring perspectives from Dr Lindsey Roeker, including the following topics:
- Consensus Approach to optimizing front-line treatment (0:00)
- Emerging role of sonrotoclax (8:39)
- Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48)
- Evolving role of minimal residual disease assessment (19:16)
Chapters
Loading chapters …
Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome
Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following …
Show notes
Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:
- Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
- Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)
- Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)
- Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)
- Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)
- Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)
- Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)
- Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)
- Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)
- Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — Microlearning Activity 2
Featuring perspectives from Dr Catherine C Coombs, including the following topics:Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously …
Show notes
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
- Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)
- Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42)
- Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50)
- Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — Microlearning Activity 1
Featuring perspectives from Dr Catherine C Coombs, including the following topics:Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia …
Show notes
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
- Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
- Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
- Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
- Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)
Chapters
Loading chapters …
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:Introduction (0:00)New and Emerging …
Show notes
Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:
- Introduction (0:00)
- New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)
- Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)
- Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management
Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:Introduction (0:00)Minimal Residual Disease Assays in Community-Based Practice (1:24)New Developments in …
Show notes
Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:
- Introduction (0:00)
- Minimal Residual Disease Assays in Community-Based Practice (1:24)
- New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)
- Richter Transformation (30:43)
- Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)
Chapters
Loading chapters …
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Featuring an interview with Dr L Elizabeth Budde, including the following topics:Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)Management of …
Show notes
Featuring an interview with Dr L Elizabeth Budde, including the following topics:
- Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
- Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
- Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
- Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
- Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
- Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)
Chapters
Loading chapters …
Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment (1:33)Bispecific Antibodies and Chimeric …
Show notes
Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
- Introduction (0:00)
- First-Line Treatment (1:33)
- Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Therapy (2:48)Relapsed/Refractory Disease …
Show notes
Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
- Introduction (0:00)
- First-Line Therapy (2:48)
- Relapsed/Refractory Disease (39:30)
Chapters
Loading chapters …
Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress
Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:Introduction (0:00)Trials in Progress (1:12)Chronic Lymphocytic Leukemia (7:09)Diffuse Large …
Show notes
Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:
- Introduction (0:00)
- Trials in Progress (1:12)
- Chronic Lymphocytic Leukemia (7:09)
- Diffuse Large B-Cell Lymphoma (32:35)
- Mantle Cell Lymphoma (58:25)
- Follicular Lymphoma (1:14:49)
Chapters
Loading chapters …
Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov
Featuring an interview with Dr Douglas W Sborov, including the following topics:DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of …
Show notes
Featuring an interview with Dr Douglas W Sborov, including the following topics:
- DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
- Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
- Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
- Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
- Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
- Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
- Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
- Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
- Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)
Chapters
Loading chapters …
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus
Featuring an interview with Prof Andreas Hochhaus, including the following topics:Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing …
Show notes
Featuring an interview with Prof Andreas Hochhaus, including the following topics:
- Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)
- Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)
- Potential mechanisms of adverse events documented with TKIs (10:23)
- Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)
- Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)
- Comparative efficacy of asciminib and other agents used to treat CML (40:01)
- Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)
- Practical care strategies for CML patients; future developments (52:32)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4
Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:Case: A woman in her mid 50s with multiple sclerosis …
Show notes
Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:
- Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)
- Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)
- Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3
Featuring perspectives from Prof John Seymour, including the following topics:Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)Venetoclax re-treatment and ongoing …
Show notes
Featuring perspectives from Prof John Seymour, including the following topics:
- Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
- Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
- First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)
Chapters
Loading chapters …
Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program
Featuring perspectives from Dr William G Wierda, including the following topics:Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)Sequencing Road Map (12:39)Key Datasets — …
Show notes
Featuring perspectives from Dr William G Wierda, including the following topics:
- Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)
- Sequencing Road Map (12:39)
- Key Datasets — Pirtobrutinib (21:08)
- Investigator Survey (34:09)
- Chimeric Antigen Receptor T-Cell Therapy (45:08)
- Other Novel Therapy Approaches (49:58)
- EHA 2026 (54:45)
Chapters
Loading chapters …
Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:Introduction: Lymphoma Survivorship (0:00)Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr …
Show notes
Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:
- Introduction: Lymphoma Survivorship (0:00)
- Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)
- Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14)
Chapters
Loading chapters …
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:Introduction (00:00)Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 …
Show notes
Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:
- Introduction (00:00)
- Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)
- Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)
- Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)
- ASCO and EHA 2026 (46:37)
Chapters
Loading chapters …
Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:Introduction (0:00)Chimeric …
Show notes
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:
- Introduction (0:00)
- Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)
- Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)
- CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10)
- Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24)
- Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47)
Chapters
Loading chapters …
Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:Introduction (0:00)The Biopathophysiology of Myelofibrosis (MF) (2:19)Current and Future Clinical …
Show notes
Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:
- Introduction (0:00)
- The Biopathophysiology of Myelofibrosis (MF) (2:19)
- Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)
- Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)
- Upcoming at European Hematology Association (EHA) 2026 (49:22)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:Introduction (0:00)Current and …
Show notes
Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:
- Introduction (0:00)
- Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)
- Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)
- Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)
- Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)
- Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)
Chapters
Loading chapters …
For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:Introduction (00:00)Role of Chimeric Antigen …
Show notes
Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:
- Introduction (00:00)
- Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
- Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
- Utility of Belantamab Mafodotin in R/R MM (49:29)
- Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1
Featuring perspectives from Dr Mazyar Shadman, including the following topics:The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) …
Show notes
Featuring perspectives from Dr Mazyar Shadman, including the following topics:
- The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)
- The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)
- Zanubrutinib-based therapy for treatment-naïve CLL (12:32)
Chapters
Loading chapters …
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2
Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:Case: A man in his mid 40s with chronic lymphocytic …
Show notes
Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:
- Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)
- Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)
- Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02)
Chapters
Loading chapters …
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:Introduction (0:00)Integrating Bispecific Antibodies …
Show notes
Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:
- Introduction (0:00)
- Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)
- Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)
- Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)
- Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24)
Chapters
Loading chapters …
These are the latest 40 of 176 episodes. You’ll find older episodes in the podcast’s feed.
Similar podcasts
More Education podcasts
Is this your podcast?
Confirm it with an entry in your feed: you get a code here, add it as podcast:txt to the channel of your feed, and we check it. Your podcast is then shown as “verified” on SoundNode.